Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Department of Clinical Immunology & Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
Clin Immunol. 2024 Jun;263:110214. doi: 10.1016/j.clim.2024.110214. Epub 2024 Apr 9.
To derive childhood-onset SLE (cSLE) specific remission definitions for future treat-to-target (T2T) trials, observational studies, and clinical practice.
The cSLE International T2T Task Force conducted Delphi surveys exploring paediatric perspectives on adult-onset SLE remission targets. A modified nominal group technique was used to discuss, refine, and agree on the cSLE remission target criteria.
The Task Force proposed two definitions of remission: 'cSLE clinical remission on steroids (cCR)' and 'cSLE clinical remission off steroids (cCR-0)'. The common criteria are: (1) Clinical-SLEDAI-2 K = 0; (2) PGA score < 0.5 (0-3 scale); (4) stable antimalarials, immunosuppressive, and biologic therapy (changes due to side-effects, adherence, weight, or when building up to target dose allowed). Criterion (3) in cCR is the prednisolone dose ≤0.1 mg/kg/day (maximum 5 mg/day), whereas in cCR-0 it is zero.
cSLE definitions of remission have been proposed, maintaining sufficient alignment with the adult-SLE definition to facilitate life-course research.
为未来的达标治疗(T2T)试验、观察性研究和临床实践制定儿童发病的系统性红斑狼疮(cSLE)特有的缓解定义。
cSLE 国际 T2T 工作组进行了德尔菲调查,探讨儿科医生对成人发病的系统性红斑狼疮缓解目标的看法。采用改良的名义小组技术对 cSLE 缓解目标标准进行讨论、完善和达成一致。
工作组提出了两种缓解定义:“cSLE 类固醇缓解(cCR)”和“cSLE 无类固醇缓解(cCR-0)”。共同标准为:(1)SLEDAI-2K 评分=0;(2)PGA 评分<0.5(0-3 分制);(4)稳定的抗疟药、免疫抑制剂和生物疗法(因副作用、依从性、体重或增加至目标剂量而改变允许)。cCR 中的标准(3)是泼尼松剂量≤0.1mg/kg/天(最大 5mg/天),而在 cCR-0 中为零。
已经提出了 cSLE 的缓解定义,与成人 SLE 定义保持足够的一致性,以促进生命过程研究。